Burzynski Research Institute Inc Revenue Growth Rates (BZYR), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Burzynski Research Institute Inc  (NONE: BZYR)
 

BZYR's Revenue Growth by Quarter and Year

Burzynski Research Institute Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BZYR Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter February -
3rd Quarter November 0.00
2nd Quarter August 0.00
1st Quarter May 0.00
FY 0.00





BZYR Revenue third quarter 2026 Y/Y Growth Comment
Burzynski Research Institute Inc in the third quarter 2026 recorded of $ 0.00 millions.

According to the results reported in the third quarter 2026, Burzynski Research Institute Inc achieved the best Revenue growth in In Vitro & In Vivo Diagnostic Substances industry. While Burzynski Research Institute Inc' s Revenue no change of 0% ranks overall at the positon no. in the third quarter 2026.


BZYR Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter February - - - -
3rd Quarter November - - - -
2nd Quarter August - - - -
1st Quarter May - - - -
FY   - - - -

Financial Statements
Burzynski Research Institute Inc's third quarter 2026 Revenue $ 0.00 millions BZYR's Income Statement
Burzynski Research Institute Inc's third quarter 2025 Revenue $ 0.00 millions Quarterly BZYR's Income Statement


BZYR Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter February - - - -
3rd Quarter November - - - -
2nd Quarter August - - - -
1st Quarter May - - - -
FY (Year on Year)   - - - -


Back to BZYR Growth rate Comparisons >> Back to BZYR Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Burzynski Research Institute Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


BZYR's III. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


BZYR's III. Quarter Q/Q Revenue Comment


Burzynski Research Institute Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Nov 30 2025)		 12 Months Ending
(Aug 31 2025)		 12 Months Ending
(May 31 2025)		 12 Months Ending
(Feb 28 2025)		 12 Months Ending
(Nov 30 2024)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #


Cumulative Revenue growth Comment
In the Nov 30 2025 period, Burzynski Research Institute Inc's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Burzynski Research Institute Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Nov 30 2025 period, Burzynski Research Institute Inc's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Burzynski Research Institute Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 






Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BZYR's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue no change for the quarter ending Nov 30 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Nov 30 2025
Medinotec Inc -1.09%$ -1.094 millions
Cryo cell International Inc -2.26%$ -2.258 millions
Neogen Corporation-2.45%$ -2.451 millions
Biomerica Inc -26.04%$ -26.039 millions


About Burzynski Research Institute Inc Revenue Growth Rates (BZYR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Burzynski Research Institute Inc (CIK 724445).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-003337
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Burzynski Research Institute Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.